By providing stable, long-term funding, these chairs can attract and retain top-tier physicians, faculty and scientists fostering world-class research and paving the way for major breakthroughs. John H. MacFarlane, president and CEO of LHSF, said the gifts are a testament to the long-standing calibre of clinical research happening in the city and the generosity of the community. “Donor generosity is the driving force behind these new endowed research chairs,” said MacFarlane. “Thanks to our donors, our local clinicians and scientists at LHSCRI are advancing research that directly benefits patients here in London. We’re proud to stand with our donors in moving this work forward.” The establishment of these chairs – Charles G. Drake Chair in Neurosurgery Research, Chair in Cardiovascular Clinical and Translational Research, Kay Family Chair in Transformational Kidney Care and Chair in Orthopaedic Research and Innovation – marks a transformative step in advancing patient care across multiple disciplines. “Through the partnership between LHSCRI and Western, we’re able to conduct research directly where care is delivered, providing access to research opportunities for patients across our region,” said Dr. Chris McIntyre, interim vice president, research at London Health Sciences Centre (LHSC) and LHSCRI scientific director. “These chairs will advance patient care outcomes and accelerate life-changing treatments through scientific exploration.”“Our longstanding partnership with the Foundation and London Health Sciences Centre Research Institute enables our research teams to work together to understand, prevent and treat some of the most difficult health challenges of our time.” – Western President Alan Shepard
New hope for patients with neurological conditions
Every year, thousands of Canadians face life-altering diagnoses that require complex brain and spinal surgeries.
Dr. David Steven, city-wide chair/department head of clinical neurological sciences – the unit where the new Charles G. Drake Chair in Neurosurgery will be held – works with a patient experiencing epileptic seizures, a condition affecting 1 in 100 people in Canada. (London Health Sciences Centre)
Evolving clinical cardiovascular care
In Canada, about one in 12 adults (2.6 million people) are living with heart disease – the second leading cause of death in the country. Cardiovascular care has come a long way, but with heart disease affecting adults as young as 20, there’s an urgency to find immediate solutions that will extend the lives of millions. The new Chair in Cardiovascular Clinical and Translational Research will strengthen clinical research in cardiovascular innovation, from mentoring learners to engaging early and mid-career scientists. The chair will help foster the next generation of leaders in cardiovascular innovation to bridge the gap between scientific discovery and patient care. This chair was made possible with $2.5 million in philanthropic support given through LHSF. The chair will be held in Schulich Medicine & Dentistry’s division of cardiology, which is internationally recognized for its leadership in research and innovation in heart disease, heart rhythm disorders and heart failure. Through an interdisciplinary approach, the chairholder will collaborate with a network of London, Ont. specialists building on clinical research to evolve cardiovascular care that improves patient outcomes.Leading in kidney screening
Kidney disease is among the most common causes of early death globally – and yet many people have no idea they are at high risk.
Dr. Amit Garg, Schulich Medicine & Dentistry’s associate dean of clinical research, nephrologist at London Health Sciences Centre and scientist at London Health Sciences Centre Research Institute, is focused on improving health outcomes for people living with kidney disease, including those needing dialysis or a transplant. (London Health Sciences Centre)












